ReachMD

Episodes 1-15 of 47

• • 

    

    Fortunato Ciardiello, MD, PhD

    Peer

  • 

    

    Erika Martinelli, MD, PhD

    Peer

  0

  

  RestartResume

  Addressing the Challenge in Rechallenge Strategies for mCRC

  Addressing the Challenge in Rechallenge Strategies for mCRC

  0.25 credits

• • 

    

    Warner K. Huh, MD

    Peer

  • 

    

    Leigh Anne Cantrell, MD, MSPH

    Peer

  7

  

  RestartResume

  Cervical Cancer Screening: The Case of the Young Patient

  Cervical Cancer Screening: The Case of the Young Patient

  0.25 credits

• • 

    

    Tanios S. Bekaii-Saab, MD

    Peer

  • 

    

    Joleen M. Hubbard, MD

    Peer

  2

  

  RestartResume

  Molecular-Driven Treatment Advances in HER2+ Metastatic Colorectal Cancer

  Molecular-Driven Treatment Advances in HER2+ Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Barbara Burtness, MD

    Peer

  • 

    

    Nabil F. Saba, MD, FACP

    Peer

  2

  

  RestartResume

  Personalizing the Treatment of Recurrent/Metastatic HNSCC: A Multifactorial Path

  Personalizing the Treatment of Recurrent/Metastatic HNSCC: A Multifactorial Path

  0.25 credits

• • 

    

    Ezra Cohen, MD, FRCPSC, FASCO

    Peer

  • 

    

    Petr Szturz, MD, PhD

    Peer

  0

  

  RestartResume

  Recent Advances and Emerging Approaches in the Treatment of Recurrent/Metastatic SCCHN: Matching the Patient to the Optimal Therapy

  Recent Advances and Emerging Approaches in the Treatment of Recurrent/Metastatic SCCHN: Matching the Patient to the Optimal Therapy

  0.25 credits

• • 

    

    Warner K. Huh, MD

    Peer

  • 

    

    Leigh Anne Cantrell, MD, MSPH

    Peer

  • 

    

    Mark H. Stoler, MD

    Peer

  27

  

  RestartResume

  Transforming Cervical Cancer Screening and Management: New Guidelines, New Tests
  A Case-Based Discussion

  Transforming Cervical Cancer Screening and Management: New Guidelines, New Tests
  A Case-Based Discussion

  0.50 credits

• • 

    

    William J. Gradishar, MD

    Peer

  • 

    

    Javier Cortes, MD, PhD

    Peer

  • 

    

    Hope S. Rugo, MD, FASCO

    Peer

  3

  

  RestartResume

  Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer

  Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer

  0.50 credits

• • 

    

    Mamta Parikh, MD, MS

    Peer

  • 

    

    Daniel P. Petrylak, MD

    Peer

  1

  

  RestartResume

  Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

  Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer

  0.50 credits

• • 

    

    Eric Jonasch, MD

    Peer

  • 

    

    Brad McGregor, MD

    Peer

  2

  

  RestartResume

  Selecting and Sequencing Immunotherapies for Patients with Advanced RCC

  Selecting and Sequencing Immunotherapies for Patients with Advanced RCC

  0.50 credits

• • 

    

    William J. Gradishar, MD

    Peer

  • 

    

    Javier Cortes, MD, PhD

    Peer

  • 

    

    Hope S. Rugo, MD, FASCO

    Peer

  4

  

  RestartResume

  Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2

  Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2

  0.50 credits

• • 

    

    Kevin J. Harrington, MBBS, PhD

    Peer

  • 

    

    Barbara Burtness, MD

    Peer

  • 

    

    Ari Rosenberg, MD

    Peer

  3

  

  RestartResume

  Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through Inhibitor of Apoptosis Protein Antagonism

  Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through Inhibitor of Apoptosis Protein Antagonism

  0.25 credits

• • 

    

    Robert L. Coleman, MD, FACOG, FACS

    Peer

  • 

    

    Susana Campos, MD, MPH

    Peer

  • 

    

    Ana Oaknin, MD, PhD

    Peer

  1

  

  RestartResume

  Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer

  Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer

  0.50 credits

• • 

    

    Robert L. Coleman, MD, FACOG, FACS

    Peer

  • 

    

    Susana Campos, MD, MPH

    Peer

  • 

    

    Domenica Lorusso, MD, PhD

    Peer

  1

  

  RestartResume

  Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies

  Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies

  0.50 credits

• • 

    

    Solange Peters, MD, PhD

    Peer

  • 

    

    Jonathan D. Spicer, MD, PhD, FRCSC

    Peer

  • 

    

    Patrick Forde, M.B.B.Ch.

    Peer

  1

  

  RestartResume

  Early Stage NSCLC: Do We Have the Right Drug, Dose, Timing, and Patient?

  Early Stage NSCLC: Do We Have the Right Drug, Dose, Timing, and Patient?

  2.50 program credits

• • 

    

    Richard S. Finn, MD

    Peer

  • 

    

    Peter R. Galle, MD

    Peer

  2

  

  RestartResume

  Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy

  Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy

  0.50 credits

• 1
• 2
• 3
• 4
• Next